DDInter1326 DDInter1676
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Olanzapine {u} (Compound) resembles {v} (Compound) Clozapine
Olanzapine {u} (Compound) resembles {v} (Compound) Pirenzepine
Olanzapine {u} (Compound) binds {v} (Gene) HTR7
Olanzapine {u} (Compound) upregulates {v} (Gene) NNT
Olanzapine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Olanzapine {u} (Compound) downregulates {v} (Gene) ITGAE
Olanzapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Olanzapine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Olanzapine (Compound) resembles Clozapine (Compound)
Olanzapine (Compound) resembles Pirenzepine (Compound)
Olanzapine (Compound) binds HTR7 (Gene)
Olanzapine (Compound) upregulates NNT (Gene)
Olanzapine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Olanzapine (Compound) downregulates ITGAE (Gene)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose
Olanzapine may lead to a major life threatening interaction when taken with Potassium chloride